Actemra (Rheumatoid Arthritis) Forecast and Market Analysis

GlobalData, November 2012, Pages: 41

Actemra (Rheumatoid Arthritis) Forecast and Market Analysis

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, Actemra (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly’s anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ’s SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.

Actemra (tocilizumab) is a first-in-class recombinant humanized mAb of the IgG1 subclass that binds to the IL-6 receptor, thus blocking its ability to increase white blood cell production which increases joint inflammation. Also, by controlling IL-6 levels, iron levels remain in check as increased IL-6 depletes stored iron levels. In May 2012, Genentech announced that the SUMMACTA study met primary endpoints showing comparable efficacy of SC Actemra 162mg weekly compared to 8mg/kg IV of Actemra. ACR 20 was achieved in both groups by Week 24. Also, data released in June 2012, showed Actemra to be significantly more effective than Humira in a head-to-head trial; results are below in the efficacy section. Currently, Actemra is the only IL-6 inhibitor approved for the treatment of moderate to severe active RA.

Scope

- Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Actemra including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Actemra for the top 10 countries from 2012 to 2022.
- Sales information covered for the US, Japan, UK, France, Germany, Spain, Italy, India, China and Australia

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Rheumatoid Arthritis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Actemra performance
- Obtain sales forecast for Actemra from 2011-2022 in the US, Japan, UK, France, Germany, Spain, Italy, India, China and Australia

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Prognosis
3.1.4 Quality of Life
3.2 Symptoms
4 Disease Management
4.1 Overview
4.2 Diagnosis
4.3 Treatment
5 Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
6 Actemra/RoActemra (tocilizumab)
6.1 Overview
6.2 Efficacy
6.3 Safety
6.4 SWOT Analysis
6.5 Forecast
7 Appendix
7.1 Abbreviations
7.2 Bibliography
7.3 Methodology
7.4 Forecasting Methodology
7.4.1 Diagnosed Rheumatoid Arthritis Patients
7.4.2 Percent Drug-treated Patients
7.4.3 General Pricing Assumptions
7.4.4 Individual Drug Assumptions
7.5 Physicians and Specialists Included in this Study
7.6 Primary Research - Prescriber Survey
7.7 About the Authors
7.7.1 Analysts
7.7.2 Global Head of Healthcare
7.8 About Us
7.9 Contact Us
7.10 Disclaimer

1.1 List of Tables
Table 1: Symptoms of Rheumatoid Arthritis
Table 2: Treatment Guidelines for Rheumatoid Arthritis
Table 3: Top Three Biologics Prescribed for Moderate-Severe Rheumatoid Arthritis by Market
Table 4: Treatment Guidelines for Rheumatoid Arthritis
Table 5: Product Profile - Actemra/RoActemra
Table 6: Actemra/RoActemra SWOT Analysis, 2012
Table 7: Global Sales Forecasts ($m) for Actemra/RoActemra
Table 8: Physicians Surveyed, By Country

1.2 List of Figures
Figure 1: Healthy and Arthritic Joint with Rheumatoid Arthritis
Figure 2: Rheumatoid Arthritis Biologic Drug Targets
Figure 3: Diagnosis Criteria for Rheumatoid Arthritis Based on 2010 ACR/EULAR Criteria Point System
Figure 4: Severity of Rheumatoid Arthritis
Figure 5: Biologic Treatment Flow Based on Updated 2012 ACR Treatment Recommendations-

Customers who bought this item also bought

• Rheumatoid Arthritis Therapeutics - Global Strategic Business Report
• Rheumatoid Arthritis (Event Driven)
• ChartTrends®: Biologics in Rheumatoid Arthritis (US) 2011
• Global Rheumatoid Arthritis Drug Pipeline Capsule - 2012 Update
• Product Profiles: Disease Modification in Rheumatoid Arthritis - Game-changing therapy close to market
• Rheumatoid Arthritis Therapeutics - Pipeline Assessment and Market Forecasts to 2018
• Special Report: The Autoimmune Biologics Pipeline-A Competitive Review
• Monoclonal Antibodies Market in Rheumatoid Arthritis to 2018 - Market Characterized by Large and Diversified Pipeline and Low Threat of Biosimilar Sales Erosion
• Monoclonal Antibodies Market to 2017 - Multiple Indication Approvals and the Potential for MAbs in Oncology and Autoimmune Diseases are Re-Shaping the Market
• Global Rheumatoid Arthritis Epidemiology and Patient Flow Analysis - 2012